Online inquiry

IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2316MR)

This product GTTS-WQ2316MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD200 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001004196.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4345
UniProt ID P41217
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2316MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10268MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ13747MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ4829MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ8252MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ7926MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ6900MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ6427MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ132MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW